|
🐜
|
Global histone modifications predict prognosis of resected non small-cell lung cancer.
8 auth.
F. Barlesi,
G. Giaccone,
M. Gallegos-Ruiz,
A. Loundou,
S. Span,
P. Lefesvre,
...
F. Kruyt,
J. Rodriguez
|
8 |
2007 |
8
🐜
|
|
🐜
|
Absence of IDH mutation identifies a novel radiologic and molecular subtype of WHO grade II gliomas with dismal prognosis
16 auth.
P. Metellus,
B. Coulibaly,
C. Colin,
A. M. Paula,
A. Vasiljevic,
D. Taieb,
A. Barlier,
B. Boisselier,
K. Mokhtari,
Xiao Wei Wang,
...
A. Loundou,
F. Chapon,
S. Pineau,
L. Ouafik,
O. Chinot,
D. Figarella-Branger
|
8 |
2010 |
8
🐜
|
|
🐬
|
Endovascular management of chronic disabling ilio-caval obstructive lesions: long-term results.
O. Hartung,
A. Loundou,
P. Barthélémy,
D. Arnoux,
M. Boufi,
Y. Alimi
|
7 |
2009 |
7
🐬
|
|
🐜
|
Long-term efficacy and safety of rituximab in IgG4-related disease: Data from a French nationwide study of thirty-three patients
29 auth.
M. Ebbo,
A. Grados,
M. Samson,
M. Groh,
A. Loundou,
A. Rigolet,
B. Terrier,
C. Guillaud,
C. Carra-Dallière,
F. Renou,
A. Pozdzik,
P. Labauge,
S. Palat,
J. Berthelot,
J. Pennaforte,
...
A. Wynckel,
C. Lebas,
N. Le Gouellec,
T. Quéméneur,
K. Dahan,
F. Carbonnel,
G. Leroux,
A. Perlat,
A. Mathian,
P. Cacoub,
E. Hachulla,
N. Costedoat-Chalumeau,
J. Harlé,
N. Schleinitz
|
7 |
2017 |
7
🐜
|
|
🐜
|
Dysembryoplastic Neuroepithelial Tumors Share with Pleomorphic Xanthoastrocytomas and Gangliogliomas BRAFV600E Mutation and Expression
11 auth.
C. Chappé,
L. Padovani,
D. Scavarda,
Fabien Forest,
I. Nanni-Metellus,
A. Loundou,
...
S. Mercurio,
F. Fina,
G. Léna,
C. Colin,
D. Figarella-Branger
|
7 |
2013 |
7
🐜
|
|
🐜
|
Synchronous multiple primary lung cancer: an increasing clinical occurrence requiring multidisciplinary management.
9 auth.
D. Trousse,
F. Barlesi,
A. Loundou,
A. Tasei,
C. Doddoli,
R. Giudicelli,
...
P. Astoul,
P. Fuentes,
P. Thomas
|
7 |
2007 |
7
🐜
|
|
🐜
|
Maintenance bevacizumab-pemetrexed after first-line cisplatin-pemetrexed-bevacizumab for advanced nonsquamous nonsmall-cell lung cancer: updated survival analysis of the AVAPERL (MO22089) randomized phase III trial.
17 auth.
F. Barlesi,
A. Scherpereel,
V. Gorbunova,
R. Gervais,
A. Vikström,
C. Chouaid,
A. Chella,
Jeong-Ho Kim,
M. Ahn,
Martin Reck,
...
A. Pazzola,
H. T. Kim,
J. Aerts,
Claire Morando,
A. Loundou,
H. Groen,
A. Rittmeyer
|
7 |
2014 |
7
🐜
|
|
🐜
|
Prospective comparison of 68Ga-DOTATATE and 18F-FDOPA PET/CT in patients with various pheochromocytomas and paragangliomas with emphasis on sporadic cases
16 auth.
Aurélien Archier,
A. Varoquaux,
P. Garrigue,
M. Montava,
Carole Guerin,
S. Gabriel,
Eva Beschmout,
I. Morange,
N. Fakhry,
F. Castinetti,
...
F. Sebag,
A. Barlier,
A. Loundou,
B. Guillet,
K. Pacak,
D. Taïeb
|
7 |
2016 |
7
🐜
|
|
🐜
|
Complications and treatment of patients with β-thalassemia in France: results of the National Registry
20 auth.
I. Thuret,
C. Pondarré,
A. Loundou,
D. Steschenko,
R. Girot,
D. Bachir,
C. Rose,
V. Barlogis,
J. Donadieu,
M. de Montalembert,
...
I. Hagège,
B. Pégourié,
C. Berger,
M. Micheau,
F. Bernaudin,
T. Leblanc,
L. Lutz,
F. Galactéros,
M. Siméoni,
C. Badens
|
6 |
2010 |
6
🐜
|
|
🐜
|
Mycophenolate mofetil monotherapy in membranous nephropathy: a 1-year randomized controlled trial.
17 auth.
B. Dussol,
S. Morange,
S. Burtey,
M. Indreies,
É. Cassuto,
G. Mourad,
E. Villar,
C. Pouteil‐Noble,
H. Karaaslan,
H. Sichez,
...
C. Lasseur,
Y. Delmas,
M. Nogier,
M. Fathallah,
A. Loundou,
V. Mayor,
Y. Berland
|
6 |
2008 |
6
🐜
|
